United States securities and exchange commission logo





                              June 15, 2020

       Lloyd M. Segal
       Chief Executive Officer
       Repare Therapeutics Inc.
       7210 Frederick-Banting, Suite 100
       St-Laurent, Qu bec, Canada H4S 2A1

                                                        Re: Repare Therapeutics
Inc.
                                                            Amendment No. 1 to
Registration Statement on Form S-1
                                                            Filed June 15, 2020
                                                            File No. 333-238822

       Dear Mr. Segal:

             We have reviewed your amended registration statement and have the
following
       comments. In some of our comments, we may ask you to provide us with
information so we
       may better understand your disclosure.

              Please respond to this letter by amending your registration
statement and providing the
       requested information. If you do not believe our comments apply to your
facts and
       circumstances or do not believe an amendment is appropriate, please tell
us why in your
       response.

              After reviewing any amendment to your registration statement and
the information you
       provide in response to these comments, we may have additional comments.

       Amendment No. 1 to Form S-1 filed June 15, 2020

       Exhibits

   1.                                                   We note that your forum
selection provision in your by-law identifies the Province of
                                                        Qu bec and appellate
courts therefrom as the exclusive forum for certain litigation,
                                                        including any
"derivative action." Please revise your prospectus to clearly describe this
                                                        provision and to
describe any risks or other impacts on investors. Risks may include, but
                                                        are not limited to,
increased costs to bring a claim and that these provisions can
                                                        discourage claims or
limit investors' ability to bring a claim in a judicial forum that they
                                                        find favorable. Also
disclose whether this provision applies to actions arising under the
                                                        Securities Act or
Exchange Act. In that regard, we note that Section 27 of the Exchange
                                                        Act creates exclusive
federal jurisdiction over all suits brought to enforce any duty or
                                                        liability created by
the Exchange Act or the rules and regulations thereunder, and Section
 Lloyd M. Segal
Repare Therapeutics Inc.
June 15, 2020
Page 2
      22 of the Securities Act creates concurrent jurisdiction for federal and
state courts over all
      suits brought to enforce any duty or liability created by the Securities
Act or the rules and
      regulations thereunder. If the provision applies to Securities Act
claims, please also revise
      your prospectus to state that there is uncertainty as to whether a court
would enforce such
      provision and that investors cannot waive compliance with the federal
securities laws and
      the rules and regulations thereunder. If this provision does not apply to
actions arising
      under the Securities Act or Exchange Act, please also ensure that the
exclusive forum
      provision in the governing document states this clearly, or tell us how
you will inform
      investors in future filings that the provision does not apply to any
actions arising under the
      Securities Act or Exchange Act.
       You may contact Tracey McKoy at (202) 551-3772 or Kate Tillan at (202)
551-3604 if
you have questions regarding comments on the financial statements and related
matters. Please
contact Tim Buchmiller at (202) 551-3635 or Joseph McCann at (202) 551-6262
with any other
questions.



                                                             Sincerely,
FirstName LastNameLloyd M. Segal
                                                             Division of
Corporation Finance
Comapany NameRepare Therapeutics Inc.
                                                             Office of Life
Sciences
June 15, 2020 Page 2
cc:       Divakar Gupta, Esq
FirstName LastName